Literature DB >> 31724120

Buspirone for the Treatment of Generalized Anxiety Disorder in Williams Syndrome: A Case Series.

Robyn P Thom1,2, Christopher J Keary1,3,2, Jessica L Waxler1, Barbara R Pober1,4, Christopher J McDougle5,6,7.   

Abstract

Co-morbid anxiety disorders, including generalized anxiety disorder (GAD), are highly prevalent among individuals with Williams syndrome (WS). However, reports of the pharmacologic treatment of only a limited number of previous anxiety disorders in WS have appeared in the literature. Here, we review the case histories of three adolescents/young adults with WS and the treatment course of co-morbid GAD with buspirone. Treatment with buspirone was well-tolerated and resulted in sustained response in all three cases. Common medical disorders in WS are highlighted with regards to safe and appropriate pharmacologic treatment of GAD. Buspirone's generally benign side effect profile is a major benefit of its use for treating GAD in individuals with WS.

Entities:  

Keywords:  Anxiety; Buspirone; Williams syndrome

Mesh:

Substances:

Year:  2020        PMID: 31724120     DOI: 10.1007/s10803-019-04301-9

Source DB:  PubMed          Journal:  J Autism Dev Disord        ISSN: 0162-3257


  29 in total

Review 1.  QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update.

Authors:  Scott R Beach; Christopher M Celano; Alan M Sugrue; Caitlin Adams; Michael J Ackerman; Peter A Noseworthy; Jeff C Huffman
Journal:  Psychosomatics       Date:  2017-11-03       Impact factor: 2.386

Review 2.  QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes.

Authors:  Katharina Wenzel-Seifert; Markus Wittmann; Ekkehard Haen
Journal:  Dtsch Arztebl Int       Date:  2011-10-14       Impact factor: 5.594

Review 3.  Hydroxyzine for generalised anxiety disorder.

Authors:  Giuseppe Guaiana; Corrado Barbui; Andrea Cipriani
Journal:  Cochrane Database Syst Rev       Date:  2010-12-08

4.  A Retrospective Chart Review of Buspirone for the Treatment of Anxiety in Psychiatrically Referred Youth with High-Functioning Autism Spectrum Disorder.

Authors:  Tolga Atilla Ceranoglu; Janet Wozniak; Ronna Fried; Maribel Galdo; Barbora Hoskova; Melissa DeLeon Fong; Joseph Biederman; Gagan Joshi
Journal:  J Child Adolesc Psychopharmacol       Date:  2018-11-16       Impact factor: 2.576

5.  Clinical effect of buspirone in autistic children.

Authors:  G M Realmuto; G J August; B D Garfinkel
Journal:  J Clin Psychopharmacol       Date:  1989-04       Impact factor: 3.153

6.  A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder.

Authors:  J P Feighner; C H Merideth; G A Hendrickson
Journal:  J Clin Psychiatry       Date:  1982-12       Impact factor: 4.384

7.  Prevalence estimation of Williams syndrome.

Authors:  Petter Strømme; Per G Bjørnstad; Kjersti Ramstad
Journal:  J Child Neurol       Date:  2002-04       Impact factor: 1.987

8.  The Pediatric Anxiety Rating Scale (PARS): development and psychometric properties.

Authors: 
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2002-09       Impact factor: 8.829

9.  Endocrine dysfunctions in children with Williams-Beuren syndrome.

Authors:  Yoon-Myung Kim; Ja Hyang Cho; Eungu Kang; Gu-Hwan Kim; Eul-Ju Seo; Beom Hee Lee; Jin-Ho Choi; Han-Wook Yoo
Journal:  Ann Pediatr Endocrinol Metab       Date:  2016-03-31

Review 10.  Anxiety Disorders in Williams Syndrome Contrasted with Intellectual Disability and the General Population: A Systematic Review and Meta-Analysis.

Authors:  R Royston; P Howlin; J Waite; C Oliver
Journal:  J Autism Dev Disord       Date:  2017-12
View more
  2 in total

Review 1.  Pharmacotherapy of Disruptive Behaviors in Children with Intellectual Disabilities.

Authors:  Gabrielle E Hodgins; Kristen Winsor; Jarrett Barnhill
Journal:  Paediatr Drugs       Date:  2022-07-04       Impact factor: 3.930

Review 2.  Williams syndrome.

Authors:  Beth A Kozel; Boaz Barak; Chong Ae Kim; Carolyn B Mervis; Lucy R Osborne; Melanie Porter; Barbara R Pober
Journal:  Nat Rev Dis Primers       Date:  2021-06-17       Impact factor: 65.038

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.